+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the reliability and validity of two new PTSD assessment tools, the Clinician Administered PTSD Scale for DSM-5 CAPS-5 and the PTSD Symptom Scale Interview for DSM-5 PSSI-5, in active duty military personnel and veterans aged 18 or older who have experienced traumatic events. The study also compares these new tools to the previous standard, the CAPS-IV, while exploring biomarkers related to PTSD such as biofluid markers, cognitive and physiological indicators, and brain activity measured by EEG. This research aims to improve diagnosis and treatment approaches for PTSD in this population. Participants are randomly assigned to one of four cohorts. Cohorts 1 and 2 focus on test-retest reliability of CAPS-5 and PSSI-5 respectively, with participants completing between two and seven visits some continue with additional visits including cognitive, behavioral assessments, and biofluid sample collection. Cohort 3 compares CAPS-5 and PSSI-5 through three visits, while Cohort 4 compares CAPS-IV and CAPS-5 over three visits, including similar assessments and sample collections. The study uses multiple visits and assessments to thoroughly evaluate the consistency and validity of these diagnostic tools. During the study, participants undergo multiple office visits where they complete PTSD assessments, cognitive and behavioral tests, and provide biofluid samples. Researchers measure test-retest reliability over intervals of about one week and six weeks, and correlations among the different PTSD assessments. Safety and mental health status are monitored throughout. The total involvement may range from two to seven visits depending on cohort and group assignment. The study collects detailed data to better understand PTSD diagnosis and related biomarkers in veterans and active duty military members.

Age: 18Years +All Genders
3 locations
B

Actively Recruiting

Healthy Volunteer

Researchers are collecting blood and tissue samples from people with and without cancer to help develop and evaluate tests for early cancer detection. This observational study aims to create a blinded reference set of blood samples from cancer and non-cancer patients to validate new blood-based multi-cancer early detection tests. The study also evaluates test performance at the time of initial cancer diagnosis by tumor type and clinical stage. Participants complete a questionnaire at the start of the study and provide blood samples at registration and again 12 months later. Patients diagnosed with cancer may also provide tissue samples at these same times. The study collects these biospecimens to help researchers study and validate early cancer detection assays in the laboratory. During the study, participants are monitored with follow-up at one year after enrollment. Researchers assess the quality and usefulness of the collected blood samples as a blinded reference set for cancer detection tests. The main outcome is the provision of these samples over up to one year, with additional evaluation of test performance by tumor type and stage. Participants involvement includes questionnaires, blood draws, and possible tissue sample collection, with no treatment interventions involved.

Age: 40Years - 75YearsAll Genders
751 locations
C

Actively Recruiting

Researchers are studying colorectal cancer incidence in people aged 45 to 70 who have 1 to 2 small, non-advanced adenomas found on colonoscopy. The trial compares two surveillance strategies performing follow-up colonoscopies at both 5 and 10 years versus only at 10 years. The goal is to better understand the timing and benefit of surveillance colonoscopy for this common condition, as current guidelines vary and lack strong randomized evidence. Participants are randomly assigned to receive either a surveillance colonoscopy at 5 and 10 years or at 10 years only after their qualifying colonoscopy. The colonoscopies will follow current quality guidelines, with all polyps completely removed during the initial exam. Standard preparation instructions will be given before each colonoscopy. This study aims to provide clear evidence on the best interval for surveillance after detecting non-advanced adenomas. During the study, participants will be monitored for colorectal cancer development over 10 years, which is the primary outcome measure. Follow-up includes scheduled colonoscopies and any necessary unscheduled procedures according to clinical need. The study will collect data on cancer incidence to guide future clinical recommendations. Participants will be followed until the study ends with safety and health closely observed throughout their participation.

Age: 45Years - 70YearsAll GendersPhase Not Applicable
499 locations
E

Actively Recruiting

Researchers are evaluating the role of genetic testing in guiding targeted treatments for patients with castration-resistant prostate cancer that has spread. This phase II trial investigates whether assigning treatments based on DNA and RNA mutations found in cancer tissue can better control tumor growth. The study aims to measure tumor response, safety, progression-free survival, overall survival, and patient-reported outcomes among other clinical and molecular factors. Participants undergo genetic testing on previously collected tumor samples and are assigned to one of three treatment groups based on molecular tumor board decisions. Treatments include valemetostat tosylate taken orally daily in 28-day cycles carboplatin and cabazitaxel given intravenously every 21 days or physician-chosen regimens such as cabazitaxel alone, abiraterone acetate with prednisone orally, enzalutamide orally, or lutetium Lu 177 vipivotide tetraxetan intravenously every 42 days for up to six cycles. Throughout the trial, patients also receive regular MRI or CT scans, bone scans, and may opt for additional PET imaging and blood sample collections. During and after treatment, participants are closely monitored through imaging and laboratory tests to assess tumor response and side effects. After completing treatment, those without disease progression have follow-up visits every two months for six months, then every three months for up to five years. The study collects data on radiographic progression, survival, prostate-specific antigen changes, skeletal events, subsequent therapies, and adverse events. Patient experiences and molecular markers are also evaluated to understand treatment response and resistance.

Age: 18Years +All GendersPhase 2
108 locations
E

Actively Recruiting

Researchers are evaluating the addition of pembrolizumab, a type of immunotherapy, to standard chemotherapy for patients with stage IIA, IIB, IIIA, or IIIB non-small cell lung cancer NSCLC that has been completely removed by surgery. This phase III trial aims to compare disease-free survival and overall survival between different treatment approaches, including chemotherapy alone and chemotherapy combined with pembrolizumab. The study also investigates side effects, drug discontinuation rates, quality of life, and specific biomarkers such as PD-L1 expression and tumor mutational burden. Participants are randomly assigned to one of two treatment groups. Both groups initially receive one of four chemotherapy regimens every 21 days for four cycles, chosen by their doctor. In one group, pembrolizumab is given after chemotherapy as an intravenous infusion every 21 days for up to 17 cycles or every 6 weeks for up to 16 cycles. In the other group, pembrolizumab is given together with chemotherapy during the initial cycles and then continued as monotherapy. Patients undergo various scans and blood tests throughout the study, including echocardiograms, MRIs, CT scans, and blood sample collections. During the trial, participants are closely monitored for disease status and side effects. Follow-up visits occur six weeks after treatment, then every three months for two years, every six months for years two to four, and annually for up to ten years after randomization. Quality of life questionnaires and symptom assessments are also completed. The main measure of success is disease-free survival, tracked for up to five years after enrollment. Safety and overall survival are reviewed for up to ten years to ensure long-term monitoring.

Age: 18Years +All GendersPhase 3
1151 locations